	meta-analysis
combination
lamivudine
hepatitis B
therapy
interferon
	conventional
rates
Heterogeneity
group
primary efficacy measures
analysis
combination
lamivudine monotherapy
patients
Treatment safety
biochemical responses
studies
trials
treatment
addition
Sustained biochemical response Greater
positive hepatitis B treatment
superior
interferon
HBeAg-positive patients
Quantitative meta-analyses
responses
lamivudine
nonadult population
monotherapy
significant differences
similar outcomes
HBeAg clearance
intention
virological

